



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Collins, A;Sundararajan, V;Millar, J;Burchell, J;Le, B;Krishnasamy, M;McLachlan, SA;Hudson, P;Mileshkin, L;Philip, J

Title:

The trajectory of patients who die from metastatic prostate cancer: a population-based study

Date:

2019-05-01

Citation:

Collins, A., Sundararajan, V., Millar, J., Burchell, J., Le, B., Krishnasamy, M., McLachlan, S. A., Hudson, P., Mileshkin, L. & Philip, J. (2019). The trajectory of patients who die from metastatic prostate cancer: a population-based study. *BJU International*, 123 (S5), pp.19-26. <https://doi.org/10.1111/bju.14593>.

Persistent Link:

<https://hdl.handle.net/11343/284687>

**Title: The trajectory of people who die from metastatic prostate cancer: A population-based study**

**Anna Collins**<sup>1\*</sup>

**Vijaya Sundararajan**<sup>1,2</sup>

**Jeremy Millar**<sup>3</sup>

**Jodie Burchell**<sup>2</sup>

**Brian Le**<sup>4</sup>

**Mei Krishnasamy**<sup>5</sup>

**Sue Anne McLachlan**<sup>6</sup>

**Peter Hudson**<sup>7,8</sup>

**Linda Mileshkin**<sup>9</sup>

**Jennifer Philip**<sup>1,10</sup>

**Affiliations**

1. Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne VIC Australia
2. Department of Public Health, La Trobe University, Melbourne VIC Australia
3. Radiation Oncology, Alfred Health, Melbourne VIC Australia
4. Parkville Integrated Palliative Care Service, Victorian Comprehensive Cancer Centre, Melbourne VIC Australia  
Medical Oncology, St Vincent's Hospital Melbourne, Melbourne VIC Australia
5. Department of Nursing, University of Melbourne, Melbourne VIC Australia
6. Medical Oncology, St Vincent's Hospital, Melbourne VIC Australia
7. Centre for Palliative Care, St Vincent's Hospital Melbourne & University of Melbourne, Melbourne VIC Australia
8. Vrije University, Brussel
9. Medical Oncology, Peter MacCallum Cancer Centre, Melbourne VIC Australia
10. Victorian Comprehensive Cancer Centre, Melbourne VIC Australia

**\*Corresponding Author**

Anna Collins

Postal: PO box 2900, Fitzroy, Melbourne, Victoria Australia 3065

**This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/bju.14593](https://doi.org/10.1111/bju.14593)**

This article is protected by copyright. All rights reserved

Address: Office 311, Level 3 Daly Wing, Cancer Services, St Vincent's Hospital Melbourne, 41  
Victoria Parade Fitzroy 3065 Victoria Australia  
Phone: +61 3 9231 1270 Email: [anna.collins@svha.org.au](mailto:anna.collins@svha.org.au)

**Funding:** Victorian Cancer Agency [ECSG14019]

**Word Count:** 2979

Author Manuscript

DR. ANNA COLLINS (Orcid ID : 0000-0003-2139-0100)

Article type : Original Article

Article category: Urological Oncology

## ABSTRACT

**Objectives:** To describe health service use, symptom and survival characteristics in mPCA in order to outline usual care practices and identify future opportunities to improve the quality of care in this patient group.

**Patients and methods:** This population cohort study, conducted in Victoria, Australia, used 10 years (2000-10) of linked hospital discharge, emergency visit and death registration data to track patients from their first inpatient admission with mPCA until death. Descriptive statistics on inpatient health service use, symptoms, procedures, survival, and place of death are presented.

**Results:** 4436 patients survived a median of 4mths (IQR 1, 12) from their first multiday admission with mPCA. They had a median of 3 admissions (IQR 1, 9), 1 emergency department presentation (IQR 0, 2) and 35 days admitted to hospital (IQR 18, 63). Lower urinary tract symptoms were common (50%), and 21% underwent lower urinary procedures, while 48% had blood product transfusions. In the last month of life, 3,685 (83%) had  $\geq 1$  indicator of aggressive end-of-life care, including 48% with more than 1 acute hospital admission, and 55% staying at least 14 days. Hospital-based palliative care was accessed by 2657 (60%), occurring a median of 30 days (IQR 11, 74) before death. Twenty-three percent died in the community, while 77% died in hospital, of whom 55% died in an acute hospital bed.

**Conclusion:** Half of all decedents first admitted for a multiday stay with mPCA survived less than 4 months thereafter. They had a marked symptom burden, underwent multiple procedures and had multiple admissions. Forty percent did not receive any hospital-based palliative care. Several opportunities exist to improve the timely transition to palliative care services with mPCA. These data form a benchmark against which future improvements to palliative care integration may be measured.

## KEY WORDS

Prostate cancer

Health services research  
End of life care  
Procedures  
Symptoms

## INTRODUCTION

Prostate cancer presents a significant challenge of mortality and morbidity for men diagnosed with this disease, their family caregivers, and for the healthcare system. Globally, it is the most common cancer in men, accounting for 1.6 million cases per year,(1) and is the second leading cause of cancer death in the US and Australia.(2, 3) Men with metastatic prostate cancer (mPCA) report multiple symptoms related to disease progression, and a rapid deterioration in quality of life during the advanced stages of their illness.(4) Of note, 60% of all healthcare expenditure attributable to prostate cancer occurs in the last 6 months of life.(5)

While 10 to 20 percent of men with prostate cancer present with metastatic disease, many others will later develop metastases despite treatment with surgery or radiotherapy.(6) Novel methods of detecting early metastatic disease(7) means that there will be marked variation in the illness trajectories experienced by this patient cohort. While overall, mPCA has a known high prevalence and substantial morbidity, little attention has been given to the palliative care needs of this population. There are limited data describing the illness trajectory of people with mPCA at the end of life,(8-10) including access to the palliative care received. Where evidence exists it is restricted to single-site cohort studies with small sample sizes.(8-10) These studies suggest interventional procedure rates of 19-25% in the final years of life, most commonly involving nephrostomy tubes, Foley catheters and transurethral resection of the prostate,(8, 9) with about half of men (52%) requiring multiple interventions. Population based data of opioid use across a range of cancers reveals that those with prostate cancer have a higher likelihood of opioid prescription (OR 2.60) than other cancers.(11) Understanding use of intensive treatments at the end of life is receiving increasing focus in the international oncology literature,(12) but is yet to be described in detail for men with prostate cancer.

Since 2010 a series of randomised trials have described benefits of palliative care integration across a range of cancers. Such benefits include improved quality of life, symptom relief, family support and greater realisation of preferences for care at the end of life.(13-16) However, genitourinary cancers, including prostate cancer, are often underrepresented in these early palliative care trials,(17-19) and the specific timing of palliative care integration for this group of patients is yet to be defined.

This study aimed to describe health service use, symptom and survival characteristics in men with mPCA at the end of life. Documenting the whole illness trajectory will outline current usual care practices and enable the identification of future opportunities to improve to the quality of care in this patient cohort.

## **PATIENTS AND METHOD**

### ***Setting***

Victoria, Australia has a population of 5.6 million.(20) All residents of Australia have universal access to publicly funded medical care provided in both community settings and in public hospitals. For approximately 51% of Australians this public coverage is complemented by private health insurance which allows access to private hospitals.(21) Palliative care is also publicly funded, can be delivered concurrently with cancer treatments, and is available across settings including in acute hospitals, community settings and in specialised inpatient palliative care units.

This study was approved by the Monash University Human Research Ethics Committee [CF11/0628] and all data were de-identified, ensuring protection of patient privacy.

### ***Data Sources***

All hospital and emergency department (ED) data in the state are compiled by individual hospitals and maintained by the Victorian State Department of Health.(22-24) The two datasets contain demographic and clinical information on each episode of patient care; their quality is maintained using an independent audit program (25, 26). Diagnostic information including symptoms is coded according to the International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM)(27), and procedural information according to the Australian Classification of Health Interventions (ACHI), 7th edition. Death certificate data are maintained by the Registry of Births, Deaths and Marriages (24).

These three datasets (hospital, emergency department and Registry of Births, Deaths and Marriages) undergo data linkage at the Victorian Department of Health.(28) Linkage staff assess data quality by a series of internal logic checks and manual review of randomly selected case groups. Notably, these data report patient contacts with hospital sectors but do not include community based care contacts.

### ***Identification of metastatic prostate cancer cases***

Metastatic prostate cancer cases were identified based on their first admission containing both primary prostate cancer (C61) and any metastatic extension (C77.0-C79.88). Patients were presumed to have metastatic prostate cancer from that admission onwards. We included only metastatic prostate cases that had their initial metastatic prostate admission on or after January 1, 2003 and who died before or on June 30, 2010. A 30-month clearance or 'lookback' period was selected during which potential cases with previous admissions for metastatic prostate cancer were excluded to ensure selection of only cases with a first mPCA admission. This timeframe was applied consistently across the included years of data, chosen based upon clinical opinion, and confirmed within the data, with 93% of prostate patients in our data that had a period between their initial metastatic prostate admission and death of 30 months or less. Only patients that resided within Victoria or a border region that fell under the Victorian hospital system were included.

## **Description of Outcome Variables**

**Sociodemographic and clinical characteristics:** Demographic and clinical characteristics were obtained from the hospital discharge data, including age group, sex, cancer diagnosis, marital status, private health insurance, country of birth, and area of residence. The relative disadvantage of their area of residence was classified using the Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage.(29) The SEIFA score for divided into quintiles based on the Victorian population and border regions that access the Victorian hospital system. The remoteness classification of the area of residence was based on the Australian Statistical Geography standard.(30)

**Cancer and treatment related symptoms and procedures:** Relevant tumour-related diagnoses, symptoms and procedures were selected based upon clinical relevance (JP, JM), a review of the literature, and the most common ICD-10-AM and ACHI codes present during the metastatic prostate admissions. This approach was employed in order to maximize face validity (expert opinion and literature review) and completeness ('bottom up' enumeration based on data). Major comorbidities were coded using the *Quan version of the Charlson Comorbidity Index*.(31)

**Palliative care utilisation:** Two indicators of access to hospital-based palliative care were defined. The first involved use of a palliative care or hospice bed, whereby the patient was principally under the care of a specialist inpatient palliative care service. The second was when the patient, cared for by a primary hospital care team, received a consultation from the specialist hospital-based palliative care services. The timing of access to palliative care (as above) was defined based on the number of days between the initiation of a palliative care approach to care and death.

**Quality of end of life care:** Aggressiveness of care, as adopted from Earle and colleagues (32) with information available in our datasets, was defined by the following parameters in the last 30 days of life: more than one ED presentation, more than one hospital admission, length of stay more than 14 days, intensive care unit admission, and inpatient chemotherapy administration within 14 days of death.

**Site of death:** Site of death was based on a combination of hospital and death certificate data in order to classify it into three mutually exclusive groups: outside hospital that is, in the community; in an inpatient hospice/palliative care bed; and in an acute care hospital bed.

## **Statistical analysis**

The illness period being described began at the time of first admission with a diagnosis of metastatic palliative care to the date of death. Care characteristics or variables were extracted for every admission from the initial metastatic prostate cancer admission onwards. Patients were classified as having a characteristic if the data indicated its presence during any admission from their initial metastatic prostate cancer admission to death, inclusive. Medians, interquartile ranges and percentages were used to describe the distribution of these variables.

Stata 13.1, Stata Corporation, College Station, Texas, USA, 2013 was used for all statistical analyses.

## **RESULTS**

### **Sample**

There were a total of 8039 patients who died with prostate cancer in the state of Victoria during the study timeframe, including 6890 (86%) who were included the hospital admission records, and an additional 1149 (14%) who were never admitted. We examined the whole care trajectory of 4436 eligible mPCA cases who died and were diagnosed with a first metastasis in the period of interest. Sixty-six percent (n=2941) were aged  $\geq 75$  years and 64% were born in Australia (Table 1). At the first hospitalisation for metastatic disease, sites of metastases were: bone, (n=3734,84%); lymph nodes, (n=475,11%); liver, (n=375,8%); lung, (n=361,8%); and 19% (n=860) had more than one metastatic site (Table 2).

### **Symptom burden**

The burden of symptoms experienced by patients increased over the illness course, including symptoms related to local problems caused by the cancer, such as lower urinary tract symptoms (which increased cumulatively from 25% to 50% from first admission with mPCA to death), and also for systemic symptoms such as confusion which affected 17% over the illness course (Table 2).

### **Medical interventions/ procedures**

The most frequent diagnostic imaging service performed for the inpatient population was computerised tomography (n=2127, 48%), while 21% had procedures to address lower urinary tract problems, and 48% had a transfusion of blood products over the course of their trajectory from first mPCA to death (Table 3).

### **Survival**

Median survival after first hospitalisation of any duration, from same-day to multiday with metastatic prostate cancer was four months, with 75% of patients (n=3252) surviving at least 30 days and 25% (n=1109) surviving over 12 months. This short median survival reflects our sampling frame, which included only those patients who died during the sampling timeframe. Twenty per cent of patients (n=890) died during their first admission with metastatic disease.

### **Patterns of care and quality of end of life care**

Between the first hospitalisation with metastatic disease and death, patients had a median of three admissions, spent a total of 35 days in hospital, with each admission a median of eight days in length (Table 4). While 61% had an emergency department presentation, this was a median of one presentation per patient.

In the final month of life, 48% had more than one acute hospitalisation, and 7% more than one emergency department presentation (Table 5). Sixty percent accessed palliative care within a median of one month prior to death, and for 64%, this access was in the final admission before death. Most patients (77%) died in hospital.

## DISCUSSION

This study details the health care use of a large cohort of patients with metastatic prostate cancer and describes their quality of end of life care within a universal access health system including palliative care services. We have demonstrated that this patient group have frequent hospitalisations at the end of life, and overall, are hospitalised for nearly one third of the time (35 days) between their first admission with metastatic disease until death (a period of median 116 days). Based upon the quality of end of life care indicators, our data indicate that patients with metastatic prostate cancer have high rates of more than one acute hospitalisation (48%), and of more than 14 days in hospital (55%) in the final month of life. These findings are associated with poorer quality of end of life care, and, as such, demonstrate opportunities to improve care in this patient group (26).

This study reveals that access to palliative care is not universal (60%) and, for the majority (64%), occurs late. These data mirror the findings of others. In a study by Roeland of 83,022 elderly patients across a range of cancers including prostate cancer, 77% were not referred to palliative care until the last 4 weeks of life,(33) suggesting that palliative care involvement is not yet a standard of care in this disease. Interestingly Roeland and colleagues noted that health system factors affect palliative care service delivery, with an increased likelihood of a palliative care consultation in geographical regions with decreased numbers of regional acute care hospital beds.(33) Meanwhile, others have demonstrated that race appears to impact upon the quality of end of life care received amongst patients with prostate cancer.(34) These findings highlight the complex social and health systems which palliative care works within, where a myriad of factors including socio-cultural, resource, health system and health professional practices may all influence referral to, or engagement with palliative care.

The recognition of need for palliative care, or the recognition of end stage disease appears to be a critical step in timely and appropriate access to palliative care. In a large Danish study of 11,062 patients, physician recognition of the terminal phase of illness occurred a median of 55 days before death, but for those with prostate cancer this recognition occurred earlier, a median of 76 days before death.(35) This indicates the potential for early recognition of the end stage of illness in prostate cancer, a finding also noted by William and colleagues, who suggested that patients with prostate cancer typically follow a different illness course at end of life to people with other cancers.(36) They suggested that prostate cancer patients typically followed a slow deterioration with worsening performance status, increasing dependency and frailty over many months.(36) They described this patient cohort as frequently requiring increasing nursing care but not necessarily intensive medical or procedural input.(36, 37)

Furthermore, in a US cohort of 3026 men with metastatic prostate cancer, Golan and colleagues demonstrated that higher rates of interventions such as more frequent PSA testing and imaging were not associated with observed survival benefits nor improvements in the quality of care at the end of life.(38) Thus, healthcare resources at this time may be better directed towards earlier palliative care input, which has been associated with significant improvements in symptoms, which are known to accompany the proposed prostate illness course of gradual deterioration to death. Studies of consecutive patients with prostate cancer presenting for outpatient consultation in the US (55 patients) and Spain (605 patients), found significant rates of urinary problems as well as high levels of pain and fatigue, the latter two symptoms closely associated with poor quality of life.(39, 40) Both these symptoms improved significantly following palliative care consultation(39). These findings of others, and data from our study demonstrate that patients with metastatic prostate cancer have significant symptom burden, and may benefit from palliative care input.

However, despite evidence that the terminal trajectory can be recognised earlier than for other cancers, in this study, timely palliative care referrals were still not always enacted. Despite a series of studies demonstrating benefits of early palliative care including improved end of life care, it appears such practice is not standardised, and many patients with metastatic prostate cancer have indicators of poor quality end of life care. While variation in practice may result from both individual clinician and 'system' level factors, as is the case with other areas of management,(41) this study demonstrates the need for guidelines to help standardise pathways to engagement with palliative care in a timely manner.

Attempts have been made to develop a standardised set of patient reported outcomes for patients with metastatic prostate cancer with a focus on symptoms of cancer and side-effects of treatment.(42) We advocate that benchmarks for palliative care engagement at standardised time-points should be added to the patient reported outcome set. We propose that the standardised time for palliative care referral should be at first multiday admission with metastatic disease,(43) as a minimum requirement, and should occur earlier if particular needs are identified. This time-point would be readily identifiable, and, based upon these data, represents a time of high health service use and poor prognosis. Access to palliative care at, or prior to, this standardised time allows for benchmarking against such a standard. As such, the data from this study may serve as an historical benchmark against which future improvements in patterns of palliative care access may be mapped.

The study has a series of limitations, including, that it is based on inpatient hospital based data only, with outpatient and community care, including community palliative care, not captured. As such, the patients included in this study were those with mPCA who required admission. Though we know a majority (86%) of all men who died with prostate care were admitted to hospital at least once, our sample likely represents the higher acuity patients. Furthermore, the data capture is of a time interval that preceded a series of landmark publications detailing benefits of palliative care which may have resulted in practice change. Such potential practice changes would not be reflected in the data within this study. Similarly, our data did not contain information on hormone-sensitive disease or refractory state, so we are not able to ascertain the impact of these factors on symptoms or health service use.

Nonetheless, the large state-wide, population-based dataset within a universal health system has enabled the documentation of the whole illness period from hospital admission until death, demonstrating state-wide patterns of all hospital care including end of life care.

Patients with metastatic prostate cancer spend substantial time in hospital in their last months, including half having two or more acute care hospitalisations in the final 30 days of life. Most die in hospital and most have at least one indicator of poor quality end of life care. These data reveal opportunities for improvement of end of life care for patients with metastatic prostate cancer, including standardisation of access to and engagement of palliative care. By standardising palliative care engagement at a designated time, benchmarks can be developed to map and improve the quality of end of life care for patients with prostate cancer. We propose future population studies detailing access to and use of palliative care based on these standardised times of engagement, to contribute to the growing body of evidence highlighting the benefit of early palliative care integration.

## **ACKNOWLEDGEMENTS**

This study was funded by the Victorian Cancer Agency [ECSG14019].

## **CONFLICTS OF INTEREST**

None declared

## **REFERENCES**

1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. *JAMA oncology*. 2017;3(4):524-48.
2. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2014.
3. Australian Institute of Health and Welfare. Prostate cancer in Australia. Canberra: AIHW; 2013.
4. Sullivan PW, Mulani PM, Fishman M, Sleep D. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. *Quality of Life Research*. 2007;16(4):571-5.
5. Krahn MD, Zagorski B, Laporte A, Alibhai SM, Bremner KE, Tomlinson G, et al. Healthcare costs associated with prostate cancer: estimates from a population-based study. *BJU international*. 2010;105(3):338-46.

6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *New England Journal of Medicine*. 2004;351(15):1502-12.
7. Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, et al. The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. *Bju international*. 2016;118:49-55.
8. Babaian K, Truong M, Cetnar J, Cross DS, Shi F, Ritter MA, et al. Analysis of urological procedures in men who died from prostate cancer using a population-based approach. *BJU international*. 2013;111(3b):E65-E70.
9. Khafagy R, Shackley D, Samuel J, O'Flynn K, Betts C, Clarke N. Complications arising in the final year of life in men dying from advanced prostate cancer. *Journal of palliative medicine*. 2007;10(3):705-11.
10. Hwang SS, Chang VT, Alejandro Y, Mulaparathi S, Cogswell J, Srinivas S, et al. Study of Hormone Refractory Prostate Cancer: Hospital Care and Palliative Care Resource Use at a VA Medical Center#. *Cancer investigation*. 2004;22(6):849-57.
11. Brelin S, Fredheim OM, Loge JH, Skurtveit S, Johannesen TB, Aass N, et al. Opioids for outpatients with cancer in their last year of life: A nationwide pharmacoepidemiological study. *Journal of opioid management*. 2016;12(1):25-36.
12. Langton JM, Blanch B, Drew AK, Haas M, Ingham JM, Pearson SA. Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: a systematic review. *Palliat Med*. 2014;28(10):1167-96.
13. Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z, et al. Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. *Journal of Clinical Oncology*. 2015;33(13):1438-45.
14. Higginson IJ, Bausewein C, Reilly CC, Gao W, Gysels M, Dzingina M, et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. *The Lancet Respiratory Medicine*. 2014;2(12):979-87.
15. Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, et al. Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. *Journal of Clinical Oncology*. 2017;35(8):834-41.
16. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *New England Journal of Medicine*. 2010;363(8):733-42.
17. Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. *JAMA*. 2009;302(7):741-9.

18. Grudzen CR, Richardson LD, Johnson PN, Hu M, Wang B, Ortiz JM, et al. Emergency department–initiated palliative care in advanced cancer: a randomized clinical trial. *JAMA oncology*. 2016;2(5):591-8.
19. Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A, et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. *The Lancet*. 2014;383(9930):1721-30.
20. Australian Bureau of Statistics. Australian Demographic Statistics 2012 [Available from: <http://www.abs.gov.au/ausstats/abs@.nsf/mf/3101.0>].
21. Australian Bureau of Statistics. Private Health Insurance: A snapshot, 2004-05 2006 [Available from: <http://www.abs.gov.au/ausstats/abs@.nsf/mf/4815.0.55.001>].
22. State Government of Victoria A, Department of Health. Victorian Emergency Minimum Dataset (VEMD) 2012 [Available from: <http://www.health.vic.gov.au/hdss/vemd/index.htm>].
23. State Government of Victoria A, Department of Health. Victorian Admitted Episodes Data Set (VAED) 2012 [Available from: <http://www.health.vic.gov.au/hdss/vaed/index.htm>].
24. State Government of Victoria A, Department of Justice. Victorian Registry of Births, Deaths and Marriages 2012 [Available from: [www.bdm.vic.gov.au](http://www.bdm.vic.gov.au)].
25. Henderson T, Shephard J, Sundararajan V. Quality of diagnosis and procedure coding in ICD-10 administrative data. *Med Care*. 2006;44(11):1011-9.
26. Department of Health V. <http://www.health.vic.gov.au/divisions/chi/office-data-integrity.htm> 2013 [
27. Wollongong Uo. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM) 2012 [Available from: <http://nccc.uow.edu.au/icd10am/icd10am/index.html>].
28. State Government of Victoria A, Department of Health. Victorian Data Linkages 2012 [Available from: <http://www.health.vic.gov.au/vdl/>].
29. Australian Bureau of Statistics. SEIFA: Socio-Economic Indexes for Areas 2008 [Available from: [http://www.abs.gov.au/websitedbs/D3310114.nsf/home/Seifa\\_entry\\_page](http://www.abs.gov.au/websitedbs/D3310114.nsf/home/Seifa_entry_page)].
30. Australian Bureau of Statistics. Australian Statistical Geography Standard (ASGS): Volume 5 - Remoteness Structure, July 2011 (cat. no. 1270.0.55.005) Canberra: ABS; 2013 [Available from: <http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1270.0.55.005Main+Features1July%202011?OpenDocument>].
31. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care*. 2005;43(11):1130-9.
32. Earle C, Landrum M, Souza J, Neville B, Weeks J, Ayanian J. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? *Journal Clinical Oncology*. 2008;26(23):3860-6.

33. Roeland EJ, Triplett DP, Matsuno RK, Boero IJ, Hwang L, Yeung HN, et al. Patterns of palliative care consultation among elderly patients with cancer. *Journal of the National Comprehensive Cancer Network*. 2016;14(4):439-45.
34. Abdollah F, Sammon JD, Majumder K, Reznor G, Gandaglia G, Sood A, et al. Racial disparities in end-of-life care among patients with prostate cancer: a population-based study. *Journal of the National Comprehensive Cancer Network*. 2015;13(9):1131-8.
35. Bell C, Nielsen MK, Neergaard MA, Guldin M-B, Jensen AB. Remaining lifetime after recognition of terminal illness depends on diagnosis: a nationwide population-based cohort study. *Journal of pain and symptom management*. 2017;53(1):116-23.
36. William L, Jackson K, Bostanci A, Ward J, Martin P, Pittman L, et al. Diagnosis matters: the differing clinical trajectories for terminal prostate, lung and haematological cancers. *Australian family physician*. 2015;44(7):479.
37. Bostanci A, Horey D, Jackson K, William L, Pittmann L, Ward J, et al. Insights into hospitalisation of advanced cancer patients: a study of medical records. *European journal of cancer care*. 2016;25(1):190-201.
38. Golan R, Bernstein AN, Gu X, Dinerman BF, Sedrakyan A, Hu JC. Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life. *Cancer*. 2018;124(10):2212-9.
39. Yennurajalingam S, Atkinson B, Masterson J, Hui D, Urbauer D, Tu SM, et al. The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients. *J Palliat Med*. 2012;15(1):20-4.
40. López-Calderero I, López-Fando L, Ríos-González E, Maisonobe P, Hernández-Yuste E, Sarmiento-Jordán M. Impact of locally advanced or metastatic prostate cancer on the quality of life. *Actas Urol Esp*. 2017;41(6):368-75.
41. Ong WL, Foroudi F, Evans S, Millar J. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate and high-risk prostate cancer. *BJU international*. 2017;120:35-42.
42. Morgans AK, Van Bommel AC, Stowell C, Abrahm JL, Basch E, Bekelman JE, et al. Development of a standardized set of patient-centered outcomes for advanced prostate cancer: an international effort for a unified approach. *European urology*. 2015;68(5):891-8.
43. Collins A, Sundararajan V, Burchell J, Millar J, McLachlan S, Krishnasamy M, et al. Transition points for the routine integration of palliative care in patients with advanced cancer. *Journal of Pain & Symptom Management*. 2018;doi: 10.1016/j.jpainsymman.2018.03.022.

**Table 1. Description of the mPCA sample (N=4,436)**

<b>Characteristic</b>	<b>No. (%)</b>
<b>Age at presentation (years)</b>	
< 65	399 (9)
65 – 74	1,096 (25)
≥ 75	2,941 (66)
<b>Country of birth</b>	
Australia	2,831 (64)
Other, English speaking	451 (10)
Other, not English speaking	1,154 (26)
<b>Remoteness classification (home residence)</b>	
Major city	2,159 (49)
Inner regional	1,574 (35)
Outer regional	527 (12)
Remote / very remote	161 (4)
Missing	15 (<1)
<b>SEIFA Index of Economic Disadvantage</b>	
Most disadvantaged: 1 <sup>st</sup> quintile	356 (8)
2 <sup>nd</sup> quintile	488 (11)
3 <sup>rd</sup> quintile	756 (17)
4 <sup>th</sup> quintile	954 (22)
Least disadvantaged: 5 <sup>th</sup> quintile	1,881 (42)
<b>Marital status</b>	
Single	1,073 (24)
Partnered	3,363 (76)
<b>Private hospital use, any</b>	2,362 (53)
<b>Survival characteristics</b>	
Months from first inpatient admission to death, median (IQR)	4 (1, 12)
Death in first admission	890 (20)

**Table 2. Burden and characterisation of disease and symptoms for people with mPCA  
(N=4,436)**

<b>Disease-related complications</b>	At first admission with metastatic disease  n (%)	Across illness course from first admission with metastatic disease until death  n (%)
<b>Sites of metastases</b>		
Bone	3,734 (84)	3,967 (89)
Brain and CNS	135 (3)	351 (8)
Lymph nodes	475 (11)	712 (16)
Liver	375 (8)	704 (16)
Lung and pleura	361 (8)	612 (14)
Other	410 (9)	718 (16)
> 1 metastatic site	860 (19)	1,773 (40)
> 2 metastatic sites	255 (6)	790 (18)
<b>Charlson comorbidity</b>		
No comorbidity present	3,214 (72)	2,170 (49)
At least one* present	1,222 (28)	2,266 (51)
<b>Lower Urinary Tract Symptoms (LUTS)</b> including obstructive, incontinence, haematuria symptoms	1,089 (25)	2,207 (50)
<b>Metabolic, nutrition &amp; endocrine complications,</b> including diabetes, dehydration, electrolyte imbalances	784 (18)	1,914 (43)
<b>Blood related complications,</b> including anaemia, thrombocytopenia	850 (19)	2,173 (49)
<b>Skeletal related complications,</b> including fractures and cord compression	452 (10)	940 (21)
<b>Psychological symptoms,</b> including mood disorders	131 (3)	411 (9)
<b>Most frequent specific symptoms and complications</b>		
Renal failure	700 (16)	1,305 (29)
Constipation	548 (12)	1,408 (32)
Nausea and vomiting	295 (7)	929 (21)
Faecal incontinence	150 (3)	410 (9)
Anorexia or severe weight loss	170 (4)	454 (10)
Pain	318 (7)	939 (21)
Fever	86 (2)	400 (9)

Fatigue	93 (2)	314 (7)
Confusion, delirium, restlessness	260 (6)	747 (17)
Infections including pulmonary, urinary	<b>883 (20)</b>	<b>2,296 (52)</b>
Rash and skin changes	122 (3)	426 (10)
<b>Total number of complications, median (IQR)</b>	1 (0, 3)	5 (3, 8)
≤1 complication	2,468 (56)	623 (14)
2 - 3 complications	997 (22)	949 (21)
≥ 4 complications	971 (22)	2,864 (65)

*Symptoms < 5% not reported; \*AMI, congestive HF, Peripheral vascular disease, cerebral vascular accident, dementia, pulmonary disease, connective tissue disorder, peptic ulcer, liver disease/ severe liver disease, diabetes with or without complications, paraplegia, renal disease, HIV*

**Table 3. Interventional procedures for people with mPCA (N=4,436)**

<b>Imaging and Interventional procedures</b>	<b>At first admission with metastatic disease</b> n (%)	<b>Across illness course from first admission with metastatic disease until death</b> n (%)
<b>Inpatient diagnostic Imaging, any*</b>	1,663 (37)	2,640 (60)
Ultrasound	93 (2)	178 (4)
X-ray	50 (1)	114 (3)
CT	1,213 (27)	2,127 (48)
MRI	310 (7)	687 (15)
Whole body nuclear medicine imaging study	750 (17)	1,087 (25)
<b>Biopsy, any site</b>	366 (8)	638 (14)
<b>Local Interventional Procedures</b>	648 (15)	1,183 (27)
<b>Upper urinary tract:</b> including ureteric catheterisation, nephrostomy tube or ureteric stent insertion	178 (4)	366 (8)
<b>Lower urinary tract:</b> including urinary (Foley) catheter insertion, subrapubic catheterisation, transurethral resection of prostate	483 (11)	945 (21)
<b>Blood/blood product transfusions</b>	810 (18)	2,124 (48)
<b>Internal Fracture fixation</b>	64 (1)	150 (3)
<b>Inpatient administration of antineoplastic agents, n (%)</b>	869 (20)	1,670 (38)
<b>Inpatient administration of radiotherapy, n (%)</b>	300 (7)	692 (16)
<b>Any interventional procedure, n (%)</b>	2,299 (52)	3,239 (73)
<b>2 or more interventional procedure, n (%)</b>	489 (11)	1,983 (45)

\*Within hospital only

**Table 4. Acute inpatient hospital use for people with mPCA (N=4436)**

<b>Admissions</b>	
Total admissions, median (IQR)	3 (1, 9)
Total same-day admissions, median (IQR)	1 (0, 5)
Same-day admission at presentation, n (%)	1,106 (25)
Intensive care use, n (%)	271 (6)
Emergency department use, n (%)	2,715 (61)
Emergency department presentation, median (IQR)	1 (0, 2)
<b>Length of stay characteristics</b>	
Total bed days, median (IQR)	35 (18, 63)
Total bed days per admission, median (IQR)	8 (4, 16)

*ED presentation only counted once for people who are transferred between ED departments; multiple episodes of care are counted as 1 admission including cross-hospital transfer*

**Table 5. Quality end-of-life care indicators for people with mPCA (N=4,436)**

<b>Aggressiveness of care</b>	n (%)
> 1 ED presentation in the last 30 days of life	311 (7)
> 1 acute hospital admission in the last 30 days of life	2,124 (48)
Length of stay $\geq$ 14 days in last 30 days of life	2,451 (55)
Intensive care admission in last 30 days of life	90 (2)
Chemotherapy in last 14 days of life	527 (12)
At least one indicator of aggressive end-of-life care	3,685 (83)
$\geq$ 2 indicators of aggressive end-of-life care	1,464 (33)
<b>Access to palliative care</b>	
No palliative care referral	1,779 (40)
Hospital-based Palliative care referral	2,657 (60)
Palliative care hospice bed, n (%)	1,744 (39)
Total bed days per palliative care admission, median (IQR)	11 (5, 22)
<b>Timing of palliative care (n=2,657)</b>	
Time (months) from first inpatient admission to referral, median (IQR)	2 (0, 10)
Time (months) from referral to death, median (IQR)	1 (0.4, 2.5)
Number of prior medical encounters before palliative care, median (IQR)	4 (2, 9)
First access in final admission, n (%)	1,700 (64)
<b>Place of death</b>	
Outside hospital	1,009 (23)
In-hospital	3,427 (77)
Acute bed	1,884 (55)
Palliative care or hospice bed	1,428 (42)
Other	115 (3)